Author: Charmaine Fraser

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, announces that Dr Christophe Chassagnole's job title has changed from Chief Operating Officer to Chief Scientific Officer.  This title aligns more closely with Dr Chassagnole's current role and responsibilities and the expectation that, going forward, he will spend more time focused on the Company's personalised...

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that it has entered into a further contract with its existing client Cancer Research UK.   Physiomics was first retained in July 2019 by Bicycle Therapeutics and Cancer Research UK to conduct Pharmacokinetics (PK), analyses (what the body does to the drug)...

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce the successful completion of its PARTNER study which was funded by a £150k “Connect” award from the National Institute for Health Research (“NIHR”) Invention for Innovation (“i4i”) programme (originally announced in March 2020).   HIGHLIGHTS The NIHR funded PARTNER study builds...

Physiomics plc (AIM: PYC), an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that all resolutions put to shareholders at the Company's annual general meeting, held earlier today at the Company’s offices in Oxford, were duly passed.   Enquiries:   Physiomics plc                                                   Dr Jim Millen, CEO +44 (0)1865 784 980   Hybridan LLP (broker) Claire Louise Noyce +44 (0) 203 764...

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded a further contract by existing client Ankyra Therapeutics (“Ankyra”). Building on the work that was announced in March this year, this contract extension is expected to complete in the first quarter of 2023.   Ankyra is a...

Physiomics to present and exhibit at SITC Annual Meeting   Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it is participating in the 37th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”), being held this week on 8-12 November 2022 in Boston, USA.   The Company will be...

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it will today publish on its website its Annual Report and Accounts for the financial year ended 30 June 2022, together with its Notice of Annual General Meeting (“AGM”).  Shareholders will be sent either printed copies of these...

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of treatment regimens for cancer and other therapeutic drugs for the biopharma industry, is pleased to announce that it is attending the #BIOEurope conference in person in Leipzig, Germany on 24-26 October 2022.   BIOEurope is one of the world’s premier biotech partnering conferences and is expected to host over 4,000 executives from over...